Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry

Objective: The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness. Study Design: Prospective observational registry enrolling those who received...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of Perinatology Vol. 28; no. 7; pp. 511 - 517
Main Authors:	Frogel, M, Nerwen, C, Cohen, A, VanVeldhuisen, P, Harrington, M, Boron, M
Format:	Journal Article
Language:	English
Published:	New York Nature Publishing Group US 01-07-2008 Nature Publishing Group
Subjects:	Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Antiviral Agents - therapeutic use Cardiovascular disease Cardiovascular diseases Children Children & youth Congenital diseases Coronary artery disease Diagnosis Disease prevention Dosage and administration Drug therapy FDA approval Gestational age Government programs Health aspects Heart diseases Hospitalization Humans Infant Infant, Newborn Infant, Premature Infants Infants (Newborn) Lung diseases Medicine Medicine & Public Health Mortality Multiple births Neuromuscular diseases original-article Palivizumab Patient outcomes Pediatric Surgery Pediatrics Prevention Prophylaxis Prospective Studies Registries Respiratory syncytial virus Respiratory syncytial virus infection Respiratory Syncytial Virus Infections - prevention & control Respiratory tract Respiratory tract diseases Risk analysis Risk factors Risk groups Seasons Siblings Tobacco smoke Viruses United States United States > US prematurity palivizumab prophylaxis respiratory syncytial virus bronchiolitis pediatrics
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Objective: The Palivizumab Outcomes Registry contains data on infants and young children who received palivizumab for the prevention of respiratory syncytial virus (RSV) that causes serious lower respiratory tract illness. Study Design: Prospective observational registry enrolling those who received ⩾1 dose of palivizumab during any RSV season (2000 to 2004) at participating US sites. Result: Of 19 548 subjects enrolled, 40% were born before 32 weeks’, 48% between 32 and 35 weeks’ and 12% after 35 weeks’ gestation. Risk factors included child-care attendance, prematurity, chronic lung disease (CLD) and congenital heart disease (CHD). The RSV hospitalization rate of palivizumab recipients was 1.3%. Gender, gestational age <32 weeks, CLD, CHD, congenital airway abnormality, severe neuromuscular disease, Medicaid insurance and >2 children in household were associated with significantly higher rates. Home-care prophylaxis with palivizumab was associated with reduced hospitalization rates. Conclusion: Data on the use of palivizumab prophylaxis in primarily high-risk infants confirm low RSV hospitalization rates.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0743-8346 1476-5543
DOI:	10.1038/jp.2008.28